Sageworth Trust Co Lowers Position in Johnson & Johnson (NYSE:JNJ)

Sageworth Trust Co lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 17.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,302 shares of the company’s stock after selling 897 shares during the period. Sageworth Trust Co’s holdings in Johnson & Johnson were worth $599,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Thoroughbred Financial Services LLC increased its position in shares of Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after purchasing an additional 1,079,751 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Johnson & Johnson by 152.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock valued at $122,372,000 after purchasing an additional 654,085 shares during the last quarter. Royal London Asset Management Ltd. increased its position in shares of Johnson & Johnson by 53.2% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock valued at $199,471,000 after purchasing an additional 648,775 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Johnson & Johnson by 2,178.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock valued at $83,759,000 after purchasing an additional 620,558 shares during the last quarter. 66.82% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson stock traded up $0.86 on Tuesday, reaching $131.02. The company’s stock had a trading volume of 110,568 shares, compared to its average volume of 7,791,626. The company has a market cap of $343.51 billion, a P/E ratio of 16.00, a price-to-earnings-growth ratio of 2.22 and a beta of 0.69. The company’s fifty day moving average price is $136.13. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the previous year, the company posted $2.10 earnings per share. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.90%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.

In other news, Director Marillyn A. Hewson acquired 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.23% of the company’s stock.

Several research firms recently issued reports on JNJ. Goldman Sachs Group began coverage on Johnson & Johnson in a research report on Tuesday, May 28th. They set a “buy” rating on the stock. Barclays began coverage on Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. BMO Capital Markets raised their price target on Johnson & Johnson from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Morgan Stanley raised their price target on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and an average price target of $148.56.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is a recession?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.